Jae Kim > DLA Piper LLP (US) > Philadelphia, United States > Lawyer Profile
DLA Piper LLP (US) Offices

ONE LIBERTY PLACE
1650 MARKET STREET, SUITE 5000
PHILADELPHIA, PA 19103-7300
PENNSYLVANIA
United States
- Firm Profile
- Go to...
Jae Kim

Work Department
Litigation, Arbitration and Investigations; Product Liability, Mass Torts and Product Stewardship; Regulatory and Government Affairs; FDA; Life Sciences; Healthcare
Position
Associate
Career
Jae Kim is an associate in DLA Piper’s FDA Regulatory Group, and advises clients in the life sciences, food and beverage, hemp and CBD, and consumer products industries.
Jae provides regulatory compliance and risk management advice to companies with products and operations subject to regulation by FDA, USDA, TTB, DEA, and FTC, as well as state regulatory authorities. Her broad regulatory practice encompasses medical devices, drugs (prescription and OTC), dietary supplements, food and beverage, alcohol, hemp and CBD products, and cosmetics.
As part of her regulatory practice, she regularly counsels clients on regulatory issues that arise throughout the product life cycle, including product development and approval strategy, current good manufacturing practices (cGMPs), state and federal licensing and registration, labeling, advertising and promotion, inspections, agreements pertaining to quality and regulatory issues, recall management, and regulatory enforcement actions.
Jae has extensive experience in conducting regulatory due diligence on behalf of companies seeking to acquire or invest in companies with a portfolio of regulated products. She also has experience in providing strategic regulatory advice and counseling for companies facing internal investigations, litigation, and arbitrations.
Jae has also advised multinational and start-up companies on navigating federal and state COVID-19 requirements, including FDA’s Emergency Use Authorization (EUA) process and enforcement discretion policies for personal protective equipment (such as face masks, face shields, gowns and gloves) as well as hand sanitizers and other medical products.
Jae serves on the Philadelphia office’s Diversity & Inclusion Committee, and is the co-manager of Cultivate, a DLA Piper blog focused on the hemp and CBD industry. She is also actively involved in the regulatory community, and serves on the Food and Drug Law Institute (FDLI)’s Cannabis Products Committee and Webinar Committee, as well as the Membership Committee of Women in Bio – Philadelphia Metro chapter.
Languages
English, Korean
Memberships
Jae serves on the Young Lawyers Editorial Board of The Legal Intelligencer, the oldest law journal in the United States.
Education
J.D., University of Notre Dame Law School; B.A., Johns Hopkins University
Top Tier Firm Rankings
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Tax > International tax
- Real estate > Land use/zoning
- International trade and national security > CFIUS
- Investment fund formation and management > Alternative/hedge funds
- Media, technology and telecoms > Outsourcing
- Intellectual property > Patents: licensing
- Intellectual property > Patents: litigation (International Trade Commission)
- M&A/corporate and commercial > Private equity buyouts: middle-market (Up to $500m)
- Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
- Real estate > Real estate
- Government > State attorneys general
- Media, technology and telecoms > Telecoms and broadcast: regulatory
- Media, technology and telecoms > Telecoms and broadcast: transactions
Firm Rankings
- Media, technology and telecoms > Advertising and marketing: transactional and regulatory
- Insurance > Advice to insurers
- Industry focus > Cannabis
- Dispute resolution > E-discovery
- Tax > Financial products
- Finance > Fintech
- Intellectual property > Patents: litigation (full coverage)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Real estate > Real estate investment trusts (REITs)
- Energy > Renewable/alternative power
- Finance > Structured finance: securitization
- Media, technology and telecoms > Technology transactions
- Intellectual property > Trademarks: non-contentious (including prosecution, portfolio management and licensing)
- Tax > US taxes: contentious
- M&A/corporate and commercial > Venture capital and emerging companies
- Labor and employment > Workplace and employment counseling
- Antitrust > Cartel
- Intellectual property > Copyright
- M&A/corporate and commercial > Corporate governance
- Labor and employment > Employee benefits, executive compensation and retirement plans: design
- Environment > Environment: regulatory
- Environment > Environment: transactional
- Insurance > Insurance: non-contentious
- Labor and employment > Labor and employment disputes (including collective actions)
- Labor and employment > Labor-management relations
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: middle-market ($500m-999m)
- Media, technology and telecoms > Media and entertainment: transactional
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- Dispute resolution > Product liability, mass tort and class action - defense: automotive/transport
- Dispute resolution > Securities litigation: defense
- Intellectual property > Trademarks: litigation
- Tax > US taxes: non-contentious
- Finance > Capital markets: equity offerings
- Antitrust > Civil litigation/class actions: defense
- Real estate > Construction (including construction litigation)
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Environment > Environment: litigation
- Dispute resolution > General commercial disputes
- Government > Government contracts
- Dispute resolution > International arbitration
- Investment fund formation and management > Private equity funds (including venture capital)
- Healthcare > Service providers
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Finance > Project finance
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Transport > Rail and road: litigation and regulation
- International trade and national security > CFIUS